BackAgeX Therapeutics Overview

AgeX Therapeutics Other Current Assets

Track AgeX Therapeutics's other current assets ($1.9M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$1.95M
31.00% YoYΔ $461000.00 vs prior year quarter

Peer average

Loading

AgeX Therapeutics Other Current Assets History

Loading

AgeX Therapeutics vs. peers: Other Current Assets Comparison

Loading

AgeX Therapeutics Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

AgeX Therapeutics (AGE) FAQ

The latest other current assets for AGE is $1.9M as of March 2026. That compares with $1.5M in the prior-year period — up 31.0% year over year. Investors often review this figure alongside AgeX Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, AGE's other current assets moved from $1.5M to $1.9M — a 31.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AgeX Therapeutics's operating scale or balance-sheet position.

A other current assets figure of $1.9M for AGE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AGE's other current assets ($1.9M), review year-over-year change from $1.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack AgeX Therapeutics's other current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.